Duplex Oligonucleotide Complexes for Serum-Resistant Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene silencing methods using RNAi face challenges in efficiently delivering oligonucleotides into cells and maintaining effective gene knockdown with minimal off-target effects and serum interference.
Innovation Solution
Development of duplex oligonucleotide complexes comprising a sense and antisense strand with significant complementarity, a cholesterol conjugate moiety, and a linker molecule, which facilitates cellular delivery and enhances gene silencing by forming stable complexes with reduced serum interference.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oligonucleotide delivery methods are used, then delivery into cells is attempted, but delivery efficiency is insufficient and serum interference occurs
Solution Approach 1:
The patent applies composite materials by creating duplex oligonucleotide complexes that combine chemically modified nucleotides (2′-O-methyl and 2′-F modifications) with cholesterol conjugates. This composite structure provides both enhanced cellular delivery capability and resistance to serum degradation, resolving the contradiction between delivery efficiency and serum interference.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of nucleotides through 2′-O-methyl and 2′-F modifications. These parameter changes in the molecular structure enhance the oligonucleotides' stability in serum and improve cellular uptake efficiency, simultaneously addressing both delivery efficiency and serum interference issues.
2Reliability
If standard RNAi oligonucleotides are used, then gene silencing is achieved, but off-target effects increase and activity duration is limited
Solution Approach 1:
The duplex complex structure with chemically modified nucleotides creates a more stable composite material that maintains gene silencing activity for extended periods. The 2′-O-methyl and 2′-F modifications enhance nuclease resistance, prolonging activity duration while the specific design reduces off-target effects.
Solution Approach 2:
The patent applies local quality by introducing specific chemical modifications at particular positions (2′-O-methyl and 2′-F modifications) within the oligonucleotide sequence. These localized modifications enhance stability and reduce off-target effects without compromising the overall gene silencing efficacy, while extending activity duration.
Data Source
AI summary
Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism.